- Report
- May 2026
- 173 Pages
Canada
From €4372EUR$4,850USD£3,756GBP
- Report
- May 2026
- 178 Pages
Japan
From €4372EUR$4,850USD£3,756GBP
- Report
- May 2026
- 181 Pages
Netherlands
From €4372EUR$4,850USD£3,756GBP
- Report
- May 2026
- 185 Pages
South Korea
From €4372EUR$4,850USD£3,756GBP
- Report
- May 2026
- 186 Pages
Spain
From €4372EUR$4,850USD£3,756GBP
- Report
- May 2026
- 187 Pages
Thailand
From €4372EUR$4,850USD£3,756GBP
- Report
- May 2026
- 188 Pages
Turkey
From €4372EUR$4,850USD£3,756GBP
- Report
- May 2026
- 189 Pages
United Kingdom
From €4372EUR$4,850USD£3,756GBP
- Report
- May 2024
- 67 Pages
South Africa
From €2028EUR$2,250USD£1,743GBP
- Report
- May 2024
- 78 Pages
North America
From €2659EUR$2,950USD£2,285GBP
- Report
- May 2024
- 86 Pages
Asia Pacific
From €3110EUR$3,450USD£2,672GBP
- Report
- March 2024
- 60 Pages
From €2659EUR$2,950USD£2,285GBP
- Report
- March 2024
- 65 Pages
Europe
From €3110EUR$3,450USD£2,672GBP
- Webinar
- August 2022
- 60 Minutes
Global
From €176EUR$195USD£151GBP

Attention Deficit Disorder (ADD) is a mental health disorder characterized by difficulty focusing, impulsivity, and hyperactivity. It is most commonly diagnosed in children, but can also affect adults. Symptoms of ADD can include difficulty paying attention, difficulty organizing tasks, restlessness, and impulsivity. Treatment for ADD typically includes medication, psychotherapy, and lifestyle changes.
The Attention Deficit Disorder market is a subset of the larger Mental Health market. It is a growing market, with an increasing number of people seeking treatment for ADD. The market is expected to continue to grow as more people become aware of the disorder and seek treatment.
Companies in the Attention Deficit Disorder market include Shire Pharmaceuticals, Novartis, and Eli Lilly. Other companies in the Mental Health market include Pfizer, Johnson & Johnson, and GlaxoSmithKline. Show Less Read more